Last reviewed · How we verify

NCT06179628

Low vs Standard Local Anesthetics Boluses for Continuous Adductor Canal Block in Total Knee Arthroplasty

Completed NA Last updated 12 August 2024
What this trial tests

NA trial testing Low bolus concentration and volume in Knee Arthropathy in 140 participants. Completed in 24 July 2024.

Timeline
9 December 2023
Primary endpoint
17 July 2024
24 July 2024

Quick facts

Lead sponsorChulalongkorn University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment140
Start date9 December 2023
Primary completion17 July 2024
Estimated completion24 July 2024
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Knee Arthropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy of two different regimens of local anesthetic boluses for continuous adductor canal block under ultrasound-guidance in total knee arthroplasty at King Chulalongkorn Memorial Hospital.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Comparison of 10 mL 0.15% vs 20 mL 0.25% bupivacaine boluses for continuous adductor canal block in total knee arthroplasty: a randomized non-inferiority trial.
    Kampitak W, Tanavalee A, Ngarmukos S, Wanasrisant N, et al · · 2025 · cited 1× · PMID 40393775 · DOI 10.1136/rapm-2025-106587

Verify or expand the search:

Other recruiting trials for Knee Arthropathy

Currently open trials in the same condition.

Other Chulalongkorn University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06179628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing